Opendata, web and dolomites


The First In Vitro Diagnostic Device for the Early Detection of Cardiac Ischemia

Total Cost €


EC-Contrib. €






 AGLYC project word cloud

Explore the words cloud of the AGLYC project. It provides you a very rough idea of what is the project "AGLYC" about.

co    stage    effectiveness    trl6    19m    medical    hrs    shortage    levels    almost    estimate    circulating    market    morbidity    cardiac    company    36m    useless    heart    either    jobs    markers    2016    vitro    accounted    restriction    deaths    ebitda    diagnostic    103m    2017    gt    2024    quantification    pharmaceutical    diagnostics    plasma    usa5eu    causing    31    risk    onset    biomarkers    death    diagnosis    advantages    man    647m    patients    min    supply    sublicense    device    completion    aglyc    damage    sensitivity    biomarker    progression    model    detects       tissue    cvd    cardiovascular    39    global    business    detecting    oxygen    tissues    ischemia    women    competitive    organ    accounting    obviously    globe    reversible    medtech    detect    rapid    care    fact    2023    70m    blood    ivd    successful    necrosis    poc    lab    irreversible    prognosis    97    glycardial    61    84    point    right    prevent    smei    diseases    90    sublicensed    2015    stratification    don    detection    demonstrates    commercialization    ischemic    apo    small    glyc    cagr   

Project "AGLYC" data sheet

The following table provides information about the project.


Organization address
postcode: 8028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2018-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLYCARDIAL DIAGNOSTICS, SL ES (BARCELONA) coordinator 50˙000.00


 Project objective

Cardiovascular diseases (CVD) are the leading cause of death/morbidity across the globe, accounting for 31% of all deaths in 2015. Early detection of ischemia (restriction in blood supply to tissues, causing oxygen shortage) is essential to prevent the progression of heart damage, but right now, we don’t have any biomarkers for the early detection of cardiac ischemia. In fact, almost 90% of the available in vitro diagnostic (IVD) methods are based on the quantification of markers of necrosis, an advanced stage of organ damage. Obviously, these methods are useless for the early detection of ischemic damage.

AGLYC is an IVD device based on the rapid quantification circulating plasma Apo J-Glyc levels as a novel biomarker for the diagnosis, prognosis and risk stratification of ischemia and ischemic tissue damage. AGLYC demonstrates a 97% sensitivity in detecting the presence of cardiac ischemia; market state of the art is 39%. It also detects ischemic damage at an early and reversible phase (30 min after ischemia onset); state of the art can only detect ischemia 6 hrs after its onset when tissue damage is irreversible. We are currently at TRL6 having the competitive advantages of high sensitivity, early detection and cost effectiveness.

The Global IVD market accounted for $61,103M in 2016 and is estimated to reach $84,647M by 2023, growing at a CAGR of 4.6% from 2017-2023. We have estimated a lab-based target market of >70M patients (USA5EU) and a Point of Care (POC) target market of >36M patients (USA5EU). Our main business model will be a sublicense model: a lab-based test will be developed and sublicensed to either a medical device company (like MedTech) or to a pharmaceutical company for the co-development and commercialization of the POC device. GlyCardial Diagnostics, S.L. is a small company of 4 (3 women, 1 man) but with the successful completion of the SMEI Phase 1 and 2 we estimate an EBITDA of around €19M, creating 10 new jobs by 2024.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AGLYC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AGLYC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TuneFork (2018)

Mobile technology that brings personalized audio into your life

Read More  

GREEN WHS (2019)


Read More  

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More